摘要
肿瘤转移是肿瘤患者的最大死因,也是临床治疗的关键瓶颈。近年来,基础和临床研究公认肿瘤微环境(TME)与肿瘤转移高度关联,成为抗肿瘤转移药物研发和临床治疗的希望所在。目前以免疫检查点抑制剂(ICIs)为代表的针对TME的主流研究过度聚焦于T细胞、B细胞的免疫纠偏作用。但是大量研究表明TME中的其他成员对于肿瘤转移的调控意义同样不容忽视,成为基于TME调节的抗转移研究进展的集中体现。该综述聚焦于肿瘤转移这一瓶颈,以近5年的文献为主,梳理了TME中非T、B免疫细胞[肿瘤相关巨噬细胞(TAMs)、肿瘤相关中性粒细胞(TANs)]和非免疫成员[血管内皮细胞(ECs)、肿瘤相关成纤维细胞(CAFs)及血小板]在肿瘤转移过程中的发挥的作用机制,挖掘了其在转移治疗中的关键价值。治疗层面上,该文着重以前沿和传统融合的视角,以TME功能稳态重塑等为切入点,归纳中医药调控非T、B免疫细胞和非免疫成员的活性、机制,并凸显其在临床转移干预中的优势特色。该文有助于突破T、B免疫细胞抗转移研究的思路局限,进一步依托于更广泛的细胞类群,拓展挖掘TME在抗转移药物干预中的潜在价值,丰富抗转移药理活性认识的思路、策略,也有望为抗转移创新药物研发提供更广阔的研究视野。
Tumor metastasis is the major cause of death for tumor patients and the key bottleneck of clinical treatment.In recent years,basic and clinical studies have recognized that tumor microenvironment(TME)is highly correlated with tumor metastasis,which provides hope for anti-metastatic drug development and clinical treatment.At present,the mainstream studies on TME represented by immune checkpoint inhibitors(ICIs)mainly focus on the rectification of immune function of T cells and B cells.However,a large number of studies have shown that the significance of other members of TME for tumor metastasis cannot be ignored,which greatly reflects the progress of anti-metastatic research based on TME regulation.This review focused on tumor metastasis,summarized the mechanism of action of non-T and non-B immune cells[tumor-associated macrophages(TAMs)and tumor-associated neutrophils(TANs)]and non-immune members[vascular endothelial cells(ECs),tumor-associated fibroblasts(CAFs),and blood platelet]in the process of tumor metastasis in TME based on the literature over the recent five years,and explored their key value in the treatment of metastasis.At the treatment level,this review focused on the perspective of the integration of frontier and traditional methods and took the functional homeostasis remodeling of TME as the entry point to summarize the activity and mechanism of traditional Chinese medicine(TCM)regulation of non-T and non-B immune cells and non-immune members and highlight its advantages and characteristics in clinical intervention of metastasis.This review helps to break through the limitations of over-reliance on T and B immune cells in anti-metastatic research,make the research rely on a wider range of cell groups,explore the potential value of TME in anti-metastatic drug intervention,and enrich the idea and strategy of understanding the anti-metastatic pharmacological activity.The review is also expected to provide a broader vision for the research and development of new anti-metastatic drugs.
作者
张阳
杨丽娜
李玉洁
杜欣珂
刘丽
李志勇
杨庆
陈颖
朱晓新
李琦
ZHANG Yang;YANG Lina;LI Yujie;DU Xinke;LIU Li;LI Zhiyong;YANG Qing;CHEN Ying;ZHU Xiaoxin;LI Qi(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2024年第13期209-218,共10页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家自然科学基金面上项目(82274129)
国家科学基金培育项目(ZXKT20016)
北京市自然科学基金项目(7232302)
中国中医科学院科技创新工程项目(CI2021A05105,CI2021B015)
中国中医科学院优秀青年科技人才(创新类)培养专项(ZZ13-YQ-044)。
关键词
肿瘤转移
肿瘤微环境
肿瘤免疫调节
中药抗转移药理学
tumor metastasis
tumor microenvironment
tumor immunomodulation
traditional Chinese medicine(TCM)anti-metastatic pharmacology
